Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland - March 22, 2024Idorsia Ltd (SIX: IDIA) today
Idorsia Ltd today announced that Guy Braunstein, who has served as Chief Medical Officer since 2022 and Head of Global Clinical Development and member of the Idorsia Executive Committee since the creation of Idorsia will retire at the end of March 2024. Guy will continue to support Idorsia as an advisor, especially in the analysis and interpretation of the data coming from the programs that he has initiated and led during his time with the company.
The CMO role was created in 2022 to ensure that Idorsia's approach to medical governance and its policies and procedures are globally aligned and consistent across Drug Discovery, Clinical Development, Pharmaceutical Development and Global and Local Medical Affairs.
"I am very pleased that with Antonio, we already have the ideal candidate to succeed Guy from within our ranks. Antonio joined Idorsia in 2020 and built our Global Medical Affairs function from the ground up. In his new role as Chief Medical Officer, Antonio will continue to ensure that we maintain our focus on ethical excellence and communicating to the medical community about our innovative portfolio.
Headquartered near Basel, Switzerland - a European biotech-hub - Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options.
Idorsia was listed on the SIX Swiss Exchange in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets.Senior Vice President, Head of Investor Relations & Corporate Communicationsinvestor.relations@idorsia.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Idorsia Pharmaceuticals Ltd: Idorsia and Viatris successfully close the transaction for the global research and development collaborationAd hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - March 18, 2024Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ:
Read more »
Idorsia Pharmaceuticals Ltd: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensivesAd hoc announcement pursuant to Art. 53 LR TRYVIO (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients
Read more »
SolarBank erwirbt Solar Flow-Through Funds Ltd. in einer Aktientransaktion im Wert von 45 Millionen Dollar- Vorabzahlung in Höhe von 25,53 Mio. Dollar und bedingte Gegenleistung in Höhe von 16,31 Mio. Dollar - bestehender Aktienbesitz der SolarBank an SFF ausgeschlossen - Solar
Read more »
ABB Ltd: ABB shareholders approve all proposals at 2024 Annual General MeetingDJ ABB Ltd: ABB shareholders approve all proposals at 2024 Annual General Meeting ABB Ltd: ABB shareholders approve all proposals at 2024 Annual General Meeting ZURICH, SWITZERLAND, March 21, 2024
Read more »
Adastra Holdings Ltd.: Adastra Holdings Announces Record Total Purchase Orders Received in January and FebruaryLANGLEY, BC / ACCESSWIRE / March 14, 2024 / Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ('Adastra' or the 'Company'), a leading cannabis processor and producer of two top Canadian concentrates brands, with
Read more »
Gabriel Resources Ltd.: Update on ICSID ArbitrationLONDON, UK / ACCESSWIRE / March 8, 2024 / Gabriel Resources Ltd. (TSXV:GBU) announces that the World Bank's International Centre for Settlement of Investment Disputes (ICSID) today issued a decision dismissing
Read more »